RESEARCH DOSSIER
Health Insurer Liquidity Stress and Claims-Paying Capacity
Abstract. Health insurers promise to finance medical care across a temporal mismatch: coverage is sold or conferred before many services occur, claims are reported and adjudicated after treatment, and cash settlement takes place through networks of providers, intermediaries, public purchasers, risk-adjustment authorities, and investment custodians. This monograph examines claims-paying capacity as a time-dependent financial and institutional capability. It distinguishes economic solvency, accounting claims liabilities, readily available cash, realizable invested assets, and the contractual or statutory capacity to settle obligations when due. The study integrates international health financing classifications, actuarial reserving scholarship, IFRS 17, IAIS risk-management requirements, European insurance liquidity planning, U.S. medical-loss-ratio and claims-payment rules, and NAIC financial observations through 2026. Original analytical work develops transparent cash-ladder identities, settlement-timing stress examples, evidence-quality checks, and a cross-institutional comparison. A consequential empirical observation is that operating cash flow and liquidity ratios may diverge: U.S. midyear 2026 health-insurer operating cash flow recovered while the NAIC-reported liquid-assets-to-current-liabilities ratio declined. The research also documents internal arithmetic inconsistencies in the published NAIC 2025 annual discussion, retaining the primary source as evidence while explicitly withholding unsupported reconciliations. Conclusions identify the cash-flow data, legal transfer restrictions, reserve-development evidence, operational capacities, and stress assumptions required to evaluate medical claims payment under adversity. The numerical scenarios are constructed illustrations, not estimates for an actual company or jurisdiction. No new proprietary theory or empirical causal finding is asserted.
Keywords: Health insurance; insurance liquidity; claims-paying capacity; medical claims; claims reserves; incurred but not reported; cash-flow stress testing; liquidity buffers; health financing; risk-based capital; actuarial uncertainty; provider payment; liquidity contingency planning; solvency; insurance supervision.
Introduction
The decisive object of health insurance liquidity research is the capacity of a financially obligated institution to transfer the right amount of money to the right claimant or healthcare provider at the legally or contractually required time. It is observed in a sequence of payments rather than at a single balance-sheet date. A health insurer may hold assets exceeding recorded liabilities while facing a transient shortage of usable settlement cash. Another insurer may experience underwriting losses yet meet immediate claims through reliable inflows, short-duration investments, or contractually available support. These are analytically distinct financial conditions with different consequences for insured persons, providers, regulators, and public financing institutions.
Health insurance adds a particularly consequential operating dimension. Claims arise from medical utilization that can change quickly with epidemics, deferred-treatment rebounds, demographic shifts, provider prices, specialty pharmaceuticals, and contract negotiations. Their presentation is delayed by clinical coding, provider submission, utilization review, eligibility reconciliation, coordination of benefits, litigation, and payment authorization. The insurer finances these obligations with premiums, employer contributions, budget transfers, capitation, subsidies, investment income, and realized asset proceeds. Cash receipt and claims settlement are rarely simultaneous.
The WHO health-financing framework identifies revenue raising, pooling, and purchasing as essential functions and recognizes the importance of timely provider disbursement for the continuity of personnel and medicines (WHO, n.d.). The OECD financing-scheme classification establishes that compulsory insurance, tax-financed arrangements, voluntary plans, and household payments coexist internationally (OECD, 2025). These observations require the researcher to state precisely whose obligation is being measured. A privately incorporated risk-bearing insurer, a statutory sickness fund, a national purchasing agency, and a third-party claims administrator have different legal access to assets, revenue support, and borrowing.
Claims-paying capacity is defined here as the demonstrated or realistically projected ability of an identified legal or public financing entity to discharge in-scope valid claims when they become payable, using legally transferable and operationally executable resources under a specified scenario and horizon. The definition has five empirical dimensions: amount, timing, asset usability, legal priority, and payment-system continuity. The ability to reject invalid claims or manage utilization belongs to claim integrity and clinical governance; it cannot be used as an unexplained substitute for liquidity.
The study asks three linked questions. First, how do medical claims creation, reporting, reserving, and payment schedules translate insured medical expenditure into cash obligations? Second, which liquidity buffers and contingent funding sources survive plausible joint shocks and operational restrictions? Third, how does claims-payment pressure interact with solvency, capital contributions, regulatory requirements, and the credibility of published indicators? The analysis uses regulatory texts, institutional statistics, official accounting explanations, and original reserving scholarship. It specifies where documentary evidence ends and conditional inference begins.
Research design and evidentiary hierarchy
Binding jurisdiction-specific legislation and contracts establish legal due dates, payment priorities, and allowed transfers. Primary actuarial research establishes the statistical scope of reserve estimation. Accounting standards describe recognition and measurement within their applicable reporting perimeter. Supervisory frameworks specify prudential expectations, while industry statistical releases provide bounded observations rather than universal causal relationships. Authorial examples illustrate accounting identities and scenario mechanics. Inferences from U.S. statutory filings are not projected mechanically onto European mutual funds or public health systems; EIOPA sector dashboard statistics are not treated as health-only observations.
A series of timely 2026 records offers a particularly useful contrast. The NAIC 2025 annual health-industry commentary reported negative 2025 operating cash flow, while its 2026 midyear report reported substantial positive operating cash flow and a lower liquidity ratio relative to midyear 2025 (NAIC, 2026a, 2026b). This divergence directs analysis toward cash-flow components, reporting periods, and balance-sheet measures. It establishes neither that all U.S. issuers were healthy nor that any specific insurer could pay all claims.
Foundations, Institutions, and Source-Critical History
A temporal conception of insurance obligations
An insurance policy or statutory entitlement connects a prospective risk-bearing promise to subsequent stochastic treatment expenditure. Prepaid funds can be pooled before insured events occur, whereas payments often follow treatment dates with uneven delays. The relevant time axes are policy coverage, service date, claim reporting, adjudication, payment authorization, bank settlement, and recovery from counterparties. Each axis has its own event and evidence record. Collapsing them into an annual ratio hides the amount of liquidity required on the date a claim becomes due.
The global institutional setting is heterogeneous. According to Health at a Glance 2025, government and compulsory insurance financing schemes together covered about three-quarters of OECD health spending in 2023 (OECD, 2025). This is an expenditure share across OECD financing categories, not a count of private insurers or a balance-sheet liquidity percentage. The OECD also explains that many social insurance schemes receive combinations of payroll contributions and government transfers. Its revenue-source comparison therefore matters for identifying the shockable inflows of a particular health fund (OECD, 2025).
The WHO's guidance on pooled revenues emphasizes that fragmented pools limit cross-subsidization and risk redistribution (WHO, n.d.). Financial pooling can make aggregate healthcare financing more resilient while leaving transferability across legally separate entities constrained. This distinction is critical. Money belonging to another risk pool, an affiliate, a government budget line, or a restricted trust cannot be counted as immediately available to the paying insurer solely because both institutions belong to a health system.
Regulatory evolution and relevance
Insurance solvency practice has increasingly integrated cash-flow and capital analysis. In the IAIS Insurance Core Principles, investment expectations address assets generating cash for claims when due (ICP 15.2.10), while liquidity-risk requirements address normal and stressed obligations (ICP 16.8), multiple time horizons, collateral needs, and intra-group funding conditions (IAIS, 2024). These statements are applicable as international supervisory standards and require review of national adoption before they are described as binding law in a specific jurisdiction.
The IFRS 17 insurance-contract standard provides a globally relevant accounting foundation where adopted, measuring groups of insurance contracts using updated fulfilment cash flows and separating insurance service and financing effects (IASB, 2017/2020). Its effective date for reporting periods beginning on or after January 1, 2023, does not establish that every public health fund or U.S. statutory insurer prepares accounts under IFRS 17. The accounting object is a measured contract liability, while the liquidity object is a dated executable payment obligation.
European regulation adds forward-looking requirements. Directive (EU) 2025/2 amended the Solvency II framework to introduce liquidity risk management planning; EIOPA's November 2025 draft technical standards specify proposed plan structure, cash-flow projections, buffer analysis, and updates (European Union, 2025; EIOPA, 2025). A draft technical standard is distinguished from an adopted binding rule, and the revised directive's transposition and application timetable must be checked against the law operative on a given assessment date. The comparative significance is methodological: the ability to settle claims is tested with dated prospective cash flows and practical monetization assumptions.
Public payment obligations and private insurance contracts
A medical provider may submit the same clinical episode to different payers under very different claims-payment laws. U.S. Medicaid's timely-claims-payment rule requires payment of 90% of qualifying practitioner clean claims within 30 days and 99% within 90 days, subject to its specified domain and exceptions (42 C.F.R. § 447.45). The parallel managed-care organization rule incorporates those standards into Medicaid MCO contracts, with contractually agreed alternative schedules permitted by the regulation (42 C.F.R. § 447.46). These are not universal insurance deadlines; statutory definitions, provider classes, claims cleanliness, exceptions, and contracts matter.
A public agency's expenditure authority, a managed-care organization's premium capitation, and a commercial insurer's claims cash account may create three different operational bottlenecks. The entity contractually obliged to pay must be the object of cash-flow analysis. The legal promise to insured individuals is important even where a provider receives direct payment. Provider solvency, insured access, and insurer solvency can transmit shocks to each other, but a delayed provider settlement does not automatically identify which institution originally lacked liquidity.
Claims Cash Timing, Reserves, and Settlement Obligations
The path from treatment to paid claim
The service-to-payment pathway includes the episode date, coding and claim submission, receipt, coverage verification, adjudication, allowed amount determination, provider or member payable recognition, payment instruction, and settled transfer. A contracted capitation payment follows a different cycle: the insurer may pay an agreed amount per member before the associated services are individually reported. Pharmacy-benefit managers and third-party administrators introduce additional reconciliation, rebates, and vendor settlement schedules. Timings vary by legal contract, payer type, and care setting.
An incurred medical loss is therefore not identical to cash paid in the same reporting interval. Under the U.S. commercial medical-loss-ratio provisions, incurred claims can include paid medical claims, unpaid claim reserves, and estimates of incurred-but-not-reported claims (45 C.F.R. § 158.140). Under the Medicaid managed-care MLR rule, the calculation also incorporates unpaid liabilities and specified quality or prevention components with a defined reporting perimeter (42 C.F.R. § 438.8). Neither annual MLR is itself a forecast of bank-transfer cash at the 7-, 30-, or 90-day horizon.
The difference between a utilization spike and cash stress depends on settlement lag. Immediate provider claims may be paid before premium recalculation, while other costs accumulate as unreported obligations. A sudden increase in utilization can thus increase reserve estimates today and cash claims later. Conversely, an accelerated adjudication campaign can produce immediate cash outflows without increasing ultimate insured medical cost. Both scenarios have actuarial importance, but their claims-paying implications are different.
Reserving, reporting development, and uncertainty
The balance of outstanding claims combines reported-but-unpaid amounts, incurred-but-not-reported events, and relevant adjustments for claim development, dispute resolution, and recoveries, subject to the applicable accounting definition. A simplified unpaid-claims identity is:
where is unpaid obligations at period end, is incurred claims recognized during the period, is paid claims, and includes properly defined revisions, transfers, or recoveries. Each term must be reconciled to the same coverage and valuation perimeter; a revised prior-year estimate cannot be silently included a second time in current incurred claims.
Classical reserving work supplies tools for estimating uncertain ultimate claims. Mack's distribution-free chain-ladder error analysis derives uncertainty measures for chain-ladder reserve estimates rather than making reserves certain (Mack, 1993). England and Verrall's stochastic reserving synthesis discusses predictive distributions, tail factors, and model families (England & Verrall, 2002). These studies originate in general insurance; applicability to medical claims requires empirical examination of changing provider contracts, coding, run-out periods, membership, and healthcare utilization.
A reserve estimate of the total amount ultimately payable is insufficient to determine the distribution of daily settlement. Suppose a portfolio has an expected remaining ultimate obligation of 100 monetary units. An assumed 30-day payment fraction of 0.30 suggests 30 units due inside the first month; a service and adjudication shock raising that fraction to 0.55 demands 55 units without changing the ultimate 100. The added 25 units are a liquidity acceleration rather than a newly estimated ultimate loss. A second shock to underlying medical costs increases both ultimate exposure and potentially the early cash fraction. An adequate stress test varies payment amount and payment timing jointly.
The IFRS 17 measurement approach distinguishes liabilities for remaining coverage and incurred claims and incorporates assumptions about fulfilment cash flows (IASB, 2017/2020). The prudential liquidity exercise must separately identify the current projected payment schedule, assets available on the same dates, and contractual ability to obtain interim funding. Measurement conventions for annual financial statements are not automatically a substitutable cash-disbursement timetable.
Claims-payment deadlines as a constraint
Payment timing includes legal and operational constraints. In the United States, the Medicaid clean-claim deadlines concern defined practitioner claims and specified exclusions, while Medicaid MCO contracts incorporate corresponding rules unless an allowed alternative schedule is agreed (42 C.F.R. §§ 447.45–447.46). A stress scenario should not count a unilateral delay in already valid claims as an available liquidity lever without identifying legal authority, patient harm, provider effects, and contractual consequences.
Payment performance is measured using actual obligations reaching maturity, not simply claims processed. Researchers should record the fraction and value of qualifying claims paid within legally defined windows, the distribution of days from receipt to settled payment, reasons for denials or reopened claims, and the incidence of disputed adjustments. A high proportion of administrative adjudications completed is compatible with delayed bank settlement. In addition, a capitation payment can be overdue even if no individual fee-for-service claim exists.
Membership and cash-flow denominators
Health insurers with rising enrollment may grow earned premium and absolute medical claims simultaneously. Reporting gross payments without member months or insured lives can confuse exposure growth with higher per-member utilization. Appropriate denominators include member months, risk-adjusted beneficiaries, completed care episodes, submitted claims, allowed claims, and beneficiary-level contributions, clearly labeled by purpose. A risk adjustment transfer is an inflow for the receiving entity and an outflow for another; sector aggregation must prevent double counting. The timing of those transfers can be material even when the annual net transfer is neutral.
A transparent research design stores claim service year, receipt quarter, payment quarter, product, contracting status, age/condition mix where lawful, and development valuation date. It separates incurred-but-not-reported estimation error, late provider submission, inflation in unit costs, newly covered therapies, claim overpayment recovery, and retroactive eligibility. The scientific result is a distribution of cash requirements conditional on observed populations and assumptions, accompanied by reserve adequacy diagnostics.
Liquidity Buffers, Contingency Funding, and Operational Execution
Available liquidity is a conditional quantity
The aggregate fair value of assets does not specify how many units can be delivered by a given deadline. Cash held in the correct legal entity and settlement account may be usable immediately. A government security may require a sale, repo arrangement, custody release, and market settlement. Investment funds may impose redemption periods. Receivables from affiliates, government transfer schemes, retrocession counterparties, or pharmacy rebates may have collection uncertainty. Pledged assets and assets required for collateral cannot be double counted as free liquidity.
The international IAIS liquidity guidance requires insurers to consider cash needs under normal and stressed conditions, asset monetization, contractual behavior, collateral posting, contingent funding, and group-level dependencies (IAIS, 2024). The related EIOPA liquidity-plan guidance calls for forecasts of incoming and outgoing cash and liquid asset buffers, with explicit attention to the uncertainty of projected support (EIOPA, 2025). These documents support an operational concept of liquidity in which time to mobilization is as important as book value.
For asset , define realized usable cash at horizon as , where is an appropriately valued unencumbered holding, the fraction operationally monetizable by the deadline, and a scenario-consistent haircut. The expression is a transparent bookkeeping device, not an asserted new regulatory metric. Use an explicit separate adjustment for settlement and transaction costs if material. For an asset pledged to support obligations, available fractions reflect only the lawfully releasable portion.
A dated cash ladder
Define opening unrestricted cash ; known and stressed inflows ; necessary claims, capitation, benefits, administration, taxes, collateral, and debt payments ; net proceeds from usable asset conversion ; and contingent funding supported by executable terms. Then
Claims-paying feasibility requires that each cash balance preceding a due payment is sufficient to execute that payment, with any designated operating floor and settlement cutoffs honored. alone does not prevent an earlier negative . The ordering of transactions matters. A multi-currency cash balance may require eligible transfers and conversion before meeting a local-currency medical claim.
Counterparty-backed liquidity is less certain than immediately usable cash. The interest, draw conditions, security, covenant compliance, notice time, renewal risk, and regulatory permissibility of credit lines are material. Future premium income depends on members remaining enrolled and paying; a government support appropriation depends on authorized timing; recoveries and rebates may be reported but uncollected. Group transfers may require regulator consent or face ring-fencing and cross-border frictions. Their survival under stress should be documented rather than assumed.
Constructed thirty-day illustration
Consider one invented health-insurance entity with 45 units of unrestricted cash and 30 units of nominal short-duration bonds. Within 30 days it expects 75 units of ordinary premium/contribution receipts and 95 units of valid claims payments, along with 12 units of required operating and other outlays. The base horizon before monetizing bonds is units of cash. This arithmetic is conditional on the receipts arriving before the claims and other payments; a weekly ladder still needs checking.
A combined shock reduces receipts to 58 units, increases the 30-day claims payments to 112 units, raises other outlays to 14, and applies an 8% liquidation haircut to bonds; suppose only 60% of the bond holding can settle inside the critical window. Its executable cash is . The stressed end-horizon cash becomes units. The entity experiences a 6.44-unit shortfall under the specified 30-day timing and sale constraints. A nominal 30-unit portfolio is not a 30-unit available-cash buffer.
Suppose a committed credit facility supplies 10 units in time and its conditions demonstrably remain satisfied under the same shock. Then terminal cash becomes units. This does not establish claims-paying feasibility if a large claim batch is due before the facility funding date. The example also excludes any additional collateral draw, premium rebate, or reinsurance receivable unless explicitly modeled. These are arithmetic identities over an invented portfolio, not calibrated outputs.
Liquidity action sequencing
Cash management choices operate through different economic channels. Collecting valid and collectible receivables earlier improves timing without changing claims liability. Shortening investment duration may improve liquidation reliability at the cost of yield. Securing contingent funding adds conditional cash and its associated interest or collateral obligations. Capital injections can replenish assets and capital if they arrive and remain available at the insured legal entity; an announced but unfunded contribution cannot clear a claim. Reinsurance changes ultimate risk transfer and possible cash recoveries, but counterparty settlement lag and collateral requirements may create a temporary gap. Negotiating prompt and predictable public subsidy transfers can reduce timing volatility.
Controls over claims fraud and erroneous payments are necessary but must respect beneficiaries' legal entitlements, provider contracts, due process, and emergency care. A reduction in payments achieved by delaying valid clean claims merely transfers liquidity stress to hospitals, clinicians, pharmacies, and patients. WHO explicitly connects timely health-provider disbursement to the availability of personnel and medicines (WHO, n.d.). Consequently, a narrowly measured improvement in insurer cash is not sufficient evidence of system-wide resilience.
Solvency–Liquidity Interaction and Stress Transmission
Two constraints on the same enterprise
Solvency assesses a firm's ability to cover its obligations with assets and an adequate capital margin under the relevant valuation and regulatory framework. Liquidity examines whether resources can meet payments as they fall due. A solvency buffer may be held as assets that take time or incur losses to monetize; a cash-rich firm may nevertheless have insufficient capital against future stochastic claims. The NAIC risk-based capital explanation describes RBC as a regulatory minimum informed by insurer scale and risk, intended to identify potential weakness rather than rank insurers universally (NAIC, 2026c).
The IAIS prudential principles explicitly connect asset and liability management, investment, capital adequacy, and liquidity (IAIS, 2024). Capital and liquidity often interact dynamically: selling bonds at a discount provides immediate cash but realizes a loss; a credit facility provides cash yet creates future debt service and contingent security demands; claims inflation raises projected liabilities while increasing imminent settlement needs. This interdependence calls for internally consistent joint scenarios.
Sector-level evidence and its boundaries
The NAIC 2025 annual results report that U.S. health-insurer annual operating cash flow was negative in 2024 and 2025, with 2025 at approximately negative $3.4 billion. The report also discusses rising benefits and loss-related payments, declining profitability, and deterioration in a published liquidity ratio (NAIC, 2026a). This is an aggregated statutory sector description, not evidence that a specific company experienced inability to settle valid medical claims.
The NAIC 2026 midyear results show the important reversal: reported operating cash flow for the half year reached approximately positive $41.7 billion, compared with approximately $4.9 billion at midyear 2025. At the same time, the report's liquid-assets-and-receivables-to-current-liabilities ratio fell from about 159% at midyear 2025 to 147% at midyear 2026 (NAIC, 2026b). A midyear operating flow cannot be compared as though it were an annualized forecast or an issuer-level liquidity stress test. The paired observations demonstrate that cash generation during a reporting interval and a balance-sheet coverage ratio at its end measure different things.
The 2026 midyear balance-sheet amounts supply an independent arithmetic reconciliation: $435.2 billion divided by $295.7 billion is approximately 1.472, consistent with a reported 147% ratio subject to rounding (NAIC, 2026b). By contrast, the annual 2025 publication's stated $477.6 billion liquid assets and receivables divided by $272.8 billion current liabilities equals approximately 175.1%, rather than its stated 152%. Likewise, its reported annual operating cash amounts of negative $1.4 billion for 2024 and negative $3.4 billion for 2025 differ by approximately $2.0 billion, although accompanying prose describes a $1.2 billion decrease. These are arithmetic mismatches between numbers within the published commentary itself, not an independently established revision to the NAIC methodology. Accordingly, this monograph quotes the disputed annual values only with that explicit warning and does not reconstruct a missing denominator, change series definitions, or claim to know which published value is erroneous.
The disparity strengthens the source-critical principle: even primary supervisory industry reports can contain reporting or editorial inconsistency. A chart label alone cannot authorize an unqualified quantified claim when its accompanying components fail basic arithmetic. The researcher should consult the underlying statutory series and any revised report before using the disputed annual indicator to calibrate a company-level cash or capital decision.
European and international context
The October 2026 EIOPA insurance dashboard assessed European insurer liquidity and funding risk at a medium level; it indicated median cash holdings near 0.7% of total assets and liquid assets near 46% at Q2 2026 (EIOPA, 2026a). Those are broad insurance-sector values and are not health-specific statistics. The June 2026 stability assessment identified persistent vulnerability to claims inflation in nonlife and health lines while describing generally strong sector solvency and liquidity (EIOPA, 2026b). It does not prove uniform resilience of each health insurer.
The updated Solvency II liquidity management provisions and the EIOPA draft technical report support projections that trace expected and stressed payment streams to eligible buffers (European Union, 2025; EIOPA, 2025). Implementation and application are matters of effective law; the scope of any exemption or proportionality measure must be checked for the undertaking and reporting date. Neither European Solvency II capital ratios nor U.S. health RBC measures may be substituted for one another without a legal and accounting mapping.
Contagion and feedback channels
Liquidity pressure may propagate from a payer to provider organizations through delayed reimbursements. Provider liquidity problems can then affect capacity, staffing, pharmaceutical inventories, and availability of treatment. A reduced delivery capacity may delay treatment, shifting future claims rather than removing economic costs. Government intervention may sustain services but require delayed appropriation or transfer flows. Group transfers can redistribute liquidity and risk across legal entities, potentially conflicting with local policyholder protection constraints.
There is also a market channel. An insurer liquidating bonds under adverse market conditions may suffer larger haircuts and spread widening, reducing its capital resources at the same time it improves immediate cash. A group with multiple insurers monetizing similar holdings simultaneously creates a correlated stress not visible in an independent-issuer deterministic test. These channels are theoretically coherent and supported by supervisory attention to market liquidity and group dependencies; their numerical magnitudes require transaction and exposure data not available in this research.
Data, Measurement, Scenario Validation, and Evidence Quality
Data architecture and unit of observation
An auditable claims-liquidity dataset requires a clearly identified paying entity and the following linked layers: coverage membership and entitlement; service and claim event; claim adjudication and payable date; settlement-bank posting; liability and reserve valuation; asset holding and encumbrance; investment cash realization; premium or statutory revenue schedule; and intercompany or fiscal transfer permissions. Personal health information must be minimized and controlled; studies can use aggregated privacy-preserving claim triangles and event-time summaries.
Three clocks require separation: the economic or clinical service date, the insurer's recognition or adjudication date, and the date bank-settled cash leaves its account. Reserve development triangles ordinarily align origin and development periods; liquidity stress adds settlement-date cohorts and executable funding. Reconciliation should tie settled claims in payment systems to cash-flow statements, while allowing clearly documented bank settlement cutoffs, payment reversals, provider advances, capitation and retrospectively adjusted claims.
A quarterly financial statement can support a general liquidity description yet remain too coarse for daily claims-payment capacity. Rapidly rising utilization may be observed first in provider encounter reports, with later impacts on billed claims and cash. A useful nowcasting system uses observed service utilization, submitted claims counts, paid-claim development, provider contract updates, and membership movement. Any estimated correction requires validation against previously held-out later payments.
Claim reserving and payment-lag validation
Mack's reserve variability method and England and Verrall's stochastic reserves discussion provide complementary lessons: point estimates need uncertainty measures and estimated future claim development requires data-sensitive assumptions (Mack, 1993; England & Verrall, 2002). Cash stress evaluation requires an additional distribution for time-to-payment, particularly when changes in claim reporting and operational processing alter lag distributions.
Validation should use rolling evaluation dates, cohort-specific holdouts, and both ultimate-cost and payment-date targets. Useful error measures are absolute cash forecast error over 7, 30, and 90 days, quantile exception rates for projected outgoing cash, backtested reserve-development bias, and counts and amounts of statutory payment-window breaches. A model that accurately predicts annual claims but repeatedly underestimates next-week cash outlays performs inadequately for this dossier's object.
The U.S. MLR claims definitions and Medicaid reporting requirements can inform definitions of paid, reserved, and unreported claims, but their annual reporting constructions must be re-expressed carefully before operational cash modeling (45 C.F.R. § 158.140; 42 C.F.R. § 438.8). Regulatory record definitions are inputs to data dictionaries, not substitutes for the settlement files themselves.
Exposure and scenario design
A scenario should record the population, business model, currency, applicable reporting standard, stress start date, time horizon, and base data vintage. Shock dimensions include claim frequency, unit price, high-cost cases, risk adjustment or public transfer timing, premium collection, enrollment, asset haircuts, market depth, collateral requirements, legal payout deadlines, information-system interruption, and counterparty default. Correlations should be justified by observed joint behavior or transparently imposed conditional assumptions.
A useful staged scenario set is a base case with contractual payment timing; adverse utilization with unchanged premium rate; delayed contribution/transfer receipts; accelerated provider settlement; market selloff affecting saleable asset value; and a combined stress that also reduces access to credit and group support. Reverse stress starts from a specified legally or operationally intolerable shortfall and works backwards to combinations of claim acceleration and delayed inflow that could produce it. These are assessment techniques; they do not create a new canonical doctrine.
A sensitivity analysis should vary payment-lag distributions and asset conversion times independently before imposing correlation. For example, an increase in 30-day claims by 15 units and a delay of premium receipts by 12 units jointly reduce cash by 27 units prior to any mitigating funding. A 10-unit reserve strengthening with no scheduled payment inside the month may affect capital yet leave that month's immediate cash unchanged. The analyst must test both facts rather than assert that every reserve movement immediately drains cash.
Data quality and primary source reconciliation
The 2026 NAIC materials demonstrate the difference between an original institutional report and an independently reproducible statistic. The midyear figures and displayed ratio reconcile approximately after division (NAIC, 2026b). The annual 2025 report's figures do not reconcile on the displayed formula, and its year-over-year operating cash-flow difference also conflicts with the reported verbal change (NAIC, 2026a). The present study treats these as two bounded source-quality exceptions. All scenario amounts are constructed separately and are not estimated from these unresolved annual numbers.
Source-check levels should distinguish direct examination of official text, a publisher-provided abstract or metadata, secondary reproduction of a regulatory text, and a numerical proposition independently recalculated from reported inputs. The accessible Mack article record establishes title, volume, pages, DOI, and abstract; it does not by itself support a claim that this project reestimated Mack's empirical examples. Similarly, England and Verrall's journal record supports their discussion of predictive reserving methods without establishing medical claims model calibration.
Scientific reproducibility and limits
The study has no access to individual insurer payment ledgers, proprietary hospital contracts, real-time liquidity risk reports, private bank settlement files, or confidential supervisory examination returns. Therefore it offers general mechanisms, verified selected published observations, and illustrative calculations; it does not claim a predictive performance statistic, individual insurer safety rating, cross-country causal effect, or completeness of all national insurance laws. A genuinely empirical extension would require time-stamped anonymized insured-claims and payment data, contractually valid cash-use restrictions, scenario backtests and audit of reported sector numerator/denominator definitions.
The research also distinguishes sector surveillance from policyholder-level security. An aggregate ratio may be compatible with liquidity shortages concentrated in an individual affiliate, region, or product. Aggregate positive operating cash flow may be dominated by a small subset of large entities. Conversely, a small public fund may enjoy a formally authorized fiscal backstop unavailable to a larger privately capitalized carrier. The comparability object is the payer's conditional due-date capacity, not the nominal size of a sector.
International Comparative Synthesis and Scientific Implications
Comparison by payer institution
For commercial medical insurers, premiums and market stabilization transfers are important cash inflows; medical reimbursement, capitation, pharmacy settlements, and administration are outflows; liquid investments and group funding may provide buffers. Ownership, statutory reserves, distributions, collateral, and insurer supervision constrain what is transferable. In U.S. Medicaid managed care, government capitation receipts and contracted provider payments make public-to-private timing especially salient; federal Medicaid MLR reporting provides relevant annual financial classifications but not a complete claims settlement ladder (CMS, n.d.).
For statutory sickness funds, contribution collection, central equalization, appropriated subsidies, and legal rights to interfund transfers determine the inflow structure. The OECD's analysis of health-financing revenues demonstrates variation in government transfers as a revenue share across compulsory insurance systems (OECD, 2025). These fractions are contextual descriptors: they do not measure liquidity quality until funding timing, collection authority, deficit rules, and backstop conditions are known.
For tax-financed public purchasers, annual appropriations and treasury disbursement procedures may dominate near-term financial feasibility. The appropriate research question is whether committed, legally deployable budget cash reaches providers by the required date. WHO's revenue–pooling–purchasing distinction provides the appropriate analytical separation (WHO, n.d.). Statutory purchasing capacity can be substantial even in the absence of an insurer-style capital surplus; budget cash limits can nonetheless delay legitimate provider payments.
For employer-sponsored self-funded arrangements, the employer commonly bears claims risk while an administrator processes claims. The employer's funding ability, payment trust or designated account, and contractual claims schedule may determine capacity. Calling the administrator the risk-bearing insurer would misidentify the entity and invalidate a solvency comparison. The contractual risk bearer must be established before selecting a denominator or stress metric.
Provider payment and social effects
Health insurer liquidity is transmitted through contracts and patient entitlements. Prompt claims payment helps maintain provider cash flow, but provider resilience depends on its broader payer mix, payroll commitments, credit facilities, and supply chain. Payment delay can impair operations without showing up as an immediate insurer capital loss. The public-health importance of timely purchasing disbursements establishes why financial analysis should jointly consider provider continuity and patient access (WHO, n.d.).
The research distinguishes legitimate correction of erroneous claims from unilateral extension of payable dates. Fraud prevention, clinical quality, and eligibility verification are separate governance duties. A payment optimization that preserves a positive cash balance by violating a prompt-payment rule or depriving a member of an owed benefit is economically incomplete and legally defective. Claims-paying capacity is evaluated under obligations as actually specified.
What international comparisons can establish
Current public records support a limited but important comparative conclusion. The IAIS insurer-level expectations and EIOPA liquidity plan work both direct attention to stressed dated cash flows, monetizable assets, contingent liquidity, and institutional controls (IAIS, 2024; EIOPA, 2025). The OECD's health financing taxonomy shows why implementation must adjust for different revenue and coverage architectures (OECD, 2025). The U.S. health-insurance 2026 midyear evidence demonstrates that liquidity stock ratios and operating cash-flow performance can move in opposite directions (NAIC, 2026b).
The conclusion from these sources is institutional and operational. Reliable claims-paying capacity requires an integrated cash-flow view with legal entity boundaries, monetary and temporal uncertainty, enforceable payment windows, and stress-tested funding assumptions. A favorable annual underwriting ratio, capital ratio, or standalone balance-sheet liquidity fraction cannot carry all of those meanings. This is a reasoned synthesis of existing accounting, financial, actuarial, and public health frameworks. It establishes no new proprietary doctrine.
Unresolved questions and high-value empirical research
Several questions demand confidential or institution-specific evidence. How large are tail correlations between high-cost medical episodes and delayed premium or government reimbursements? Which provider claims are genuinely accelerated under administrative modernization, and what does this do to the required buffer? What proportion of published sector liquid assets is readily mobilizable under market stress and group-transfer restrictions? How do capitation, fee-for-service, and pharmaceutical rebate schedules alter the volatility of cash receipts and payouts? Under what contract terms does reinsurance deliver liquidity before a large cluster of medical claims matures?
A further question concerns the value of independent reporting verification. When an official source's ratios do not reconcile with its displayed components, is the explanation a differing denominator perimeter, an omitted adjustment, a data revision, or an editorial error? The NAIC annual example makes this a concrete priority rather than a speculative concern. Source reconciliation is part of scientific evidence quality and should accompany any operational use of reported ratios.
Conclusion
Claims-paying capacity is a due-date capability anchored in the legal and operational conditions of a particular health insurance payer. Its measurement requires a dated sequence of valid medical payments, premiums or fiscal transfers, unrestricted starting cash, executable asset monetization, and reliably available contingency funding. Claims reserving establishes estimates of liability development and uncertainty; it must be connected to payment-lag distributions before it becomes a short-term liquidity forecast. Solvency and liquidity interact through claims deterioration, asset sales, funding covenants, counterparty exposures, and capital decisions, while remaining distinct supervisory and analytical questions.
The research finds that international health financing institutions vary materially in cash sources, legal boundaries, and available backstops. U.S. statutory health insurers, Medicaid managed-care organizations, statutory sickness funds, public purchasing agencies, and self-funded employers require different entity-level models even when all ultimately finance medical treatment. Primary standards and legislation support multi-horizon liquidity assessment and the protection of valid payment obligations. Publicly released 2026 NAIC sector data illustrate both the divergence of cash-flow and balance-sheet indicators and the need to reconcile internally inconsistent annual source figures before calibration.
The author's original contribution is a source-critical synthesis of health-specific cash obligation formation, dated funding feasibility, enforceable settlement windows, reserve uncertainty, and international institutional comparability, supported by transparent, fully hypothetical arithmetic. A research-ready empirical agenda emerges: join claims and funding data at actual settlement dates, identify transferable asset cash by legal entity, validate forecast distributions against observed payment delays, and report both financial and service-continuity effects. No new theory, proprietary model, empirical discovery, or external peer-review determination is claimed.
Technical Appendix: Auditable Cash-Ladder Illustrations
Appendix A — Base and stressed 30-day cash
All amounts are invented monetary units. Base: opening cash 45; receipts 75; required claims 95; other outflows 12; bond liquidation 0; committed loan 0. Terminal amount = 45 + 75 − 95 − 12 = 13.
Stress: opening cash 45; receipts 58; required claims 112; other outflows 14; bond holding 30; eligible saleable share 0.60; haircut 0.08; bond cash = 30 × 0.60 × (1 − 0.08) = 16.56. Terminal amount = 45 + 58 + 16.56 − 112 − 14 = −6.44. Timely committed funding 10 brings terminal cash to 3.56 if and only if the facility can be drawn before all relevant payment due dates.
Appendix B — Settlement acceleration without higher ultimate claims
Estimated remaining ultimate claims = 100 units. Base projected 30-day fraction = 0.30, so 30-day payments = 30. Accelerated projected fraction = 0.55, so 30-day payments = 55. Incremental near-term liquidity need = 25, with unchanged remaining ultimate claims by assumption. This is a pure timing stress, excluding any later clawback or changes in medical cost.
Appendix C — Published-ratio internal consistency check
For the NAIC June 2026 figures, 435.2 / 295.7 = 1.4718, rounding to approximately 147% as reported. For its reported December 2025 inputs, 477.6 / 272.8 = 1.7507, or approximately 175%, while the annual text identifies a ratio of 152%. The annual displayed inputs and ratio do not reconcile if treated as one simple numerator/denominator pair. Likewise negative 3.4 minus negative 1.4 = negative 2.0, in billions, versus the annual narrative's stated decrease of 1.2. No corrected official series is inferred from this check.
References
Centers for Medicare & Medicaid Services (CMS). n.d. “Medical Loss Ratio (MLR): Medicaid Managed Care Guidance.” U.S. Department of Health and Human Services. Medicaid MLR guidance.
England, P. D., and R. J. Verrall. 2002. “Stochastic Claims Reserving in General Insurance.” British Actuarial Journal 8 (3): 443–518. https://doi.org/10.1017/S1357321700003809. Journal publication.
European Insurance and Occupational Pensions Authority (EIOPA). 2025. Final Report on Draft Regulatory Technical Standards on Liquidity Risk Management Plans: Solvency II Review. EIOPA-BoS-25/386, November 17. Official report page.
European Insurance and Occupational Pensions Authority (EIOPA). 2026a. Insurance Risk Dashboard: October 2026. EIOPA-BoS-26-495. Official dashboard.
European Insurance and Occupational Pensions Authority (EIOPA). 2026b. Financial Stability Report: June 2026. Frankfurt: EIOPA. Financial Stability Report.
European Union. 2025. Directive (EU) 2025/2 of the European Parliament and of the Council of 27 November 2024 amending Directive 2009/138/EC as regards proportionality, quality of supervision, reporting, long-term guarantee measures, macro-prudential tools, sustainability risks and group and cross-border supervision. Official Journal of the European Union, January 8, 2025. Directive (EU) 2025/2.
International Accounting Standards Board (IASB). 2017, amended 2020. IFRS 17: Insurance Contracts. IFRS Foundation; annual periods beginning on or after January 1, 2023. IFRS 17 standard.
International Association of Insurance Supervisors (IAIS). 2024. Insurance Core Principles and Common Framework for the Supervision of Internationally Active Insurance Groups, adopted December 2024; in particular ICP 15 and ICP 16. Basel: IAIS. IAIS official online tool.
Mack, Thomas. 1993. “Distribution-Free Calculation of the Standard Error of Chain Ladder Reserve Estimates.” ASTIN Bulletin 23 (2): 213–225. https://doi.org/10.2143/AST.23.2.2005092. Journal publication; publisher abstract and metadata.
National Association of Insurance Commissioners (NAIC). 2026a. U.S. Health Insurance Industry: 2025 Annual Results. Kansas City, MO: NAIC. Annual industry commentary.
National Association of Insurance Commissioners (NAIC). 2026b. U.S. Health Insurance Industry: 2026 Mid-Year Results. Kansas City, MO: NAIC. Midyear industry results.
National Association of Insurance Commissioners (NAIC). 2026c. “Risk-Based Capital.” Insurance Topics; last updated June 30, 2026. RBC regulatory explanation.
Organisation for Economic Co-operation and Development (OECD). 2025. Health at a Glance 2025: OECD Indicators. Paris: OECD Publishing. DOI: 10.1787/8f9e3f98-en. Health expenditure by financing scheme.
Organisation for Economic Co-operation and Development (OECD). 2025. “Public Funding of Health Spending.” In Health at a Glance 2025: OECD Indicators. Paris: OECD Publishing. Public funding chapter.
United States. Code of Federal Regulations. 42 C.F.R. § 438.8. “Medical Loss Ratio (MLR) Standards,” as amended through 2024 in the cited consolidated text. Medicaid MLR regulation.
United States. Code of Federal Regulations. 42 C.F.R. § 447.45. “Timely Claims Payment.” Medicaid payment rule.
United States. Code of Federal Regulations. 42 C.F.R. § 447.46. “Timely Claims Payment by MCOs.” Medicaid MCO payment rule.
United States. Code of Federal Regulations. 45 C.F.R. § 158.140. “Reimbursement for Clinical Services Provided to Enrollees,” as amended through 2025 in the cited consolidated text. Commercial MLR claims definition.
World Health Organization (WHO). n.d. “Health Financing.” Geneva: WHO. Health financing overview.
World Health Organization (WHO). n.d. “Pooling Revenues and Reducing Fragmentation.” Geneva: WHO. Pooling guidance.